FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892333732> ?p ?o ?g. }

• W2892333732 endingPage "10510" @default.
• W2892333732 startingPage "10510" @default.
• W2892333732 abstract "10510 Background: Larotrectinib is the first selective small-molecule inhibitor of TRKA, B, and C in clinical development. Data from the adult phase I trial demonstrate prolonged responses in patients (pts) with TRK fusions and a favorable tolerability profile. Methods: This multicenter, rolling 6 phase I study enrolled pts with refractory solid or CNS tumors aged ≥ 1 month – 21 years. Pts were dosed orally BID on a continuous 28-day schedule either by capsule or solution. Pharmacokinetic (PK)-directed intra-subject dose escalation was permitted, with exposures targeting the adult recommended Phase II dose (RP2D) of 100 mg BID. The primary objective was to define the MTD / RP2D; secondary objectives included PK and efficacy using RECIST v1.1. Results: As of December 31, 2016, 17 pts (12 with TRK fusions, 5 without TRK fusions) with a median age of 5.2 years (0.4 – 18.3) were enrolled to 3 dose levels. Pts were enrolled with fusions of all 3 NTRK genes: NTRK1 (n=6), NTRK2 (n=1), and NTRK3 (n=5) in heterogeneous tumor diagnoses: infantile fibrosarcoma (IFS) (n=6), other sarcoma (n=4), and papillary thyroid cancer (n=2). Most common AEs regardless of attribution were vomiting, diarrhea, and fatigue. While 8 (47%) pts experienced grade 3-4 AEs, none were attributed to larotrectinib. No DLTs were observed and an MTD was not established. Both formulations delivered dose-dependent PK comparable to the adult RP2D at dose level 3. 12 pts (10 with TRK fusions, 2 without TRK fusions) remain on treatment with median follow-up of 2.8 months (0.7 – 8.4). Among TRK fusion pts, the vast majority have achieved confirmed RECIST responses regardless of tumor diagnoses. No responses were seen in pts without TRK fusions (n=4). 5 pts discontinued therapy, including 2 with TRK fusions: 1 pt with IFS had sufficient response to allow tumor resection, and 1 pt with IFS progressed with a documented acquired resistance mutation. Conclusions: Larotrectinib has demonstrated a favorable tolerability profile and histology-independent efficacy in pediatric pts harboring TRK fusions. Updated safety and efficacy data will be presented, including the RP2D, response rate, duration of response, and use of larotrectinib in the pre-surgical setting. Clinical trial information: NCT02637687." @default.
• W2892333732 created "2018-09-27" @default.
• W2892333732 creator A5001066329 @default.
• W2892333732 creator A5004056259 @default.
• W2892333732 creator A5005083505 @default.
• W2892333732 creator A5010557443 @default.
• W2892333732 creator A5031896106 @default.
• W2892333732 creator A5032304577 @default.
• W2892333732 creator A5037223340 @default.
• W2892333732 creator A5046880941 @default.
• W2892333732 creator A5071801742 @default.
• W2892333732 creator A5078388888 @default.
• W2892333732 creator A5083808934 @default.
• W2892333732 creator A5087551014 @default.
• W2892333732 date "2017-05-20" @default.
• W2892333732 modified "2023-10-01" @default.
• W2892333732 title "A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family." @default.
• W2892333732 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10510" @default.
• W2892333732 hasPublicationYear "2017" @default.
• W2892333732 type Work @default.
• W2892333732 sameAs 2892333732 @default.
• W2892333732 citedByCount "11" @default.
• W2892333732 countsByYear W28923337322017 @default.
• W2892333732 countsByYear W28923337322018 @default.
• W2892333732 countsByYear W28923337322020 @default.
• W2892333732 crossrefType "journal-article" @default.
• W2892333732 hasAuthorship W2892333732A5001066329 @default.
• W2892333732 hasAuthorship W2892333732A5004056259 @default.
• W2892333732 hasAuthorship W2892333732A5005083505 @default.
• W2892333732 hasAuthorship W2892333732A5010557443 @default.
• W2892333732 hasAuthorship W2892333732A5031896106 @default.
• W2892333732 hasAuthorship W2892333732A5032304577 @default.
• W2892333732 hasAuthorship W2892333732A5037223340 @default.
• W2892333732 hasAuthorship W2892333732A5046880941 @default.
• W2892333732 hasAuthorship W2892333732A5071801742 @default.
• W2892333732 hasAuthorship W2892333732A5078388888 @default.
• W2892333732 hasAuthorship W2892333732A5083808934 @default.
• W2892333732 hasAuthorship W2892333732A5087551014 @default.
• W2892333732 hasConcept C111113717 @default.
• W2892333732 hasConcept C112705442 @default.
• W2892333732 hasConcept C121332964 @default.
• W2892333732 hasConcept C126322002 @default.
• W2892333732 hasConcept C134139212 @default.
• W2892333732 hasConcept C142424586 @default.
• W2892333732 hasConcept C143998085 @default.
• W2892333732 hasConcept C170493617 @default.
• W2892333732 hasConcept C171034665 @default.
• W2892333732 hasConcept C197934379 @default.
• W2892333732 hasConcept C2778375690 @default.
• W2892333732 hasConcept C71924100 @default.
• W2892333732 hasConcept C87355193 @default.
• W2892333732 hasConcept C90924648 @default.
• W2892333732 hasConcept C92020748 @default.
• W2892333732 hasConceptScore W2892333732C111113717 @default.
• W2892333732 hasConceptScore W2892333732C112705442 @default.
• W2892333732 hasConceptScore W2892333732C121332964 @default.
• W2892333732 hasConceptScore W2892333732C126322002 @default.
• W2892333732 hasConceptScore W2892333732C134139212 @default.
• W2892333732 hasConceptScore W2892333732C142424586 @default.
• W2892333732 hasConceptScore W2892333732C143998085 @default.
• W2892333732 hasConceptScore W2892333732C170493617 @default.
• W2892333732 hasConceptScore W2892333732C171034665 @default.
• W2892333732 hasConceptScore W2892333732C197934379 @default.
• W2892333732 hasConceptScore W2892333732C2778375690 @default.
• W2892333732 hasConceptScore W2892333732C71924100 @default.
• W2892333732 hasConceptScore W2892333732C87355193 @default.
• W2892333732 hasConceptScore W2892333732C90924648 @default.
• W2892333732 hasConceptScore W2892333732C92020748 @default.
• W2892333732 hasIssue "15_suppl" @default.
• W2892333732 hasLocation W28923337321 @default.
• W2892333732 hasOpenAccess W2892333732 @default.
• W2892333732 hasPrimaryLocation W28923337321 @default.
• W2892333732 hasRelatedWork W1537289008 @default.
• W2892333732 hasRelatedWork W1934667138 @default.
• W2892333732 hasRelatedWork W2014468166 @default.
• W2892333732 hasRelatedWork W2074207917 @default.
• W2892333732 hasRelatedWork W2090169689 @default.
• W2892333732 hasRelatedWork W2538072326 @default.
• W2892333732 hasRelatedWork W2765994429 @default.
• W2892333732 hasRelatedWork W3159937175 @default.
• W2892333732 hasRelatedWork W4298086959 @default.
• W2892333732 hasRelatedWork W4366822339 @default.
• W2892333732 hasVolume "35" @default.
• W2892333732 isParatext "false" @default.
• W2892333732 isRetracted "false" @default.
• W2892333732 magId "2892333732" @default.
• W2892333732 workType "article" @default.